About this trial
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Older than 18 years
Able to give informed consent
Undergoing coronary angiography.
Disqualifiers
Patients younger than 18 years
Unable to give consent
Pregnancy
Dialysis
Trial design
Parallel
Treatments tested in this trial
Arterial blood sample
Biological/VaccineAn arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.
Treatment groups
Trial outcomes
Primary outcomes
Platelet GARP expression
The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.
Secondary outcomes
Inflammatory profile
The inflammatory cytokines (IL-1, IL-6, TNF,...) profile will be determined by multiplex and compared between arms.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Université Catholique de Louvain
Lead sponsor
Fonds National de la Recherche Scientifique
Collaborator
This trial is not recruiting at the moment. You can still explore other options: